B6-hOSMR Mouse

The oncostatin M receptor (OSMR) gene encodes the OSMRβ protein subunit, which is widely expressed in the skin (in keratinocytes), liver (in hepatocytes), and various immune cells. This protein subunit forms heterodimeric complexes with the signal transduction subunit gp130 (or IL-31Rα), serving as functional receptors for two key inflammatory cytokines: oncostatin M (OSM) and interleukin-31 (IL-31), respectively. Upon binding of these cytokines to their receptors, the JAK/STAT signaling pathway is primarily activated, thereby regulating multiple critical biological processes, including inflammatory responses, immune responses, and tissue regeneration. Dysregulation of the OSMR signaling pathway is closely linked to the pathophysiological processes of various diseases. In dermatology, mutations in the OSMR gene are the direct cause of primary localized cutaneous amyloidosis (PLCA), a rare hereditary disorder ^[1]. Meanwhile, excessive activation of this pathway (particularly the IL-31 axis) acts as a core driver of pruritus and inflammation in chronic inflammatory skin diseases such as atopic dermatitis ^[2]. In oncology, OSMR-based therapies hold potential for treating various cancers, including cervical squamous cell carcinoma and lung adenocarcinoma ^[3-4]. Given its central role in inflammation-driven processes and the tumor microenvironment, the OSMR signaling pathway has emerged as a key target for drug development.

B6-hOSMR mouse is a humanized model constructed by replacing the coding sequences of exon 2 and partial intron 2 sequence of the murine Osmr gene with the Kozak-OSMR chimeric CDS-3'UTR of mouse Osmr-WPRE-BGH pA expression cassette. This model is applicable to mechanistic research on inflammatory diseases (e.g., rheumatoid arthritis, atopic dermatitis), cancers (cervical squamous cell carcinoma, lung adenocarcinoma, pancreatic cancer), cardiovascular diseases (e.g., atherosclerosis), liver diseases (e.g., fibrosis), and hematopoietic and bone marrow-related disorders. It also supports the screening, development, and safety evaluation of OSMR-targeted drugs.